Christine Hann

Associate Professor

19982019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Christine Hann is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
HhAntag691 Medicine & Life Sciences
Heterografts Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Camptothecin Medicine & Life Sciences
Type I DNA Topoisomerase Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer

Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K., Ashok Sivakumar, I. K., Bruhm, D. C., Rosner, S., Phallen, J., Leal, A., Adleff, V., Smith, K. N., Cottrell, T. R., Rhymee, L., Palsgrove, D. N., Hann, C. L., Levy, B., Feliciano, J. & 16 others, Georgiades, C., Verde, F., Illei, P., Li, Q. K., Gabrielson, E., Brock, M. V., Isbell, J. M., Sauter, J. L., Taube, J., Scharpf, R. B., Karchin, R., Pardoll, D. M., Chaft, J. E., Hellmann, M. D., Brahmer, J. R. & Velculescu, V. E., Jan 1 2019, In : Cancer Research. 79, 6, p. 1214-1225 12 p.

Research output: Contribution to journalArticle

Open Access
Non-Small Cell Lung Carcinoma
DNA
Neoplasms
Therapeutics
Confidence Intervals

Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: Results from the phase II TrINITY study

Morgensztern, D., Besse, B., Greillier, L., Santana-Davila, R., Ready, N., Hann, C. L., Glisson, B. S., Farago, A. F., Dowlati, A., Rudin, C. M., Le Moulec, S., Lally, S., Yalamanchili, S., Wolf, J., Govindan, R. & Carbone, D. P., Dec 1 2019, In : Clinical Cancer Research. 25, 23, p. 6958-6966 9 p.

Research output: Contribution to journalArticle

Open Access
Small Cell Lung Carcinoma
Safety
Immunohistochemistry
Rabbits
delta protein

Lung cancer and family-centered concerns

Feliciano, J., Chang, A., Venkatraman, D., Brooks, S., Zagaja, C., Ettinger, D. S., Hann, C., Naidoo, J., Voong, K., Hales, R., Turner, M., Peterson, V. & Bodurtha, J. N., Jan 1 2019, In : Supportive Care in Cancer.

Research output: Contribution to journalArticle

Lung Neoplasms
Focus Groups
Caregivers
Neoplasms
Family Health

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

Ready, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., Salvagni, S., Taylor, M., Amin, A., Camidge, D. R., Horn, L., Calvo, E., Li, A., Lin, W. H., Callahan, M. K. & Spigel, D. R., Jan 1 2019, (Accepted/In press) In : Journal of Thoracic Oncology.

Research output: Contribution to journalArticle

Open Access
Small Cell Lung Carcinoma
Survival
ipilimumab
nivolumab
Disease Progression
Non-Small Cell Lung Carcinoma
Pneumonia
Radiotherapy
Thorax
Ligands